# Diabetes Research Hub — Daily Monitor Report
**Date:** 2026-04-12 (Sunday) | **Run:** #23

## Summary
Fixed 3 research path validation statuses that were not persisted in Run 22. Processed 5 search_pubmed work queue items. Added 1 new paper (PMID 40907678). All 39 pipeline scripts passed. Credibility sweep clean.

## Work Queue Items Processed

### 1. Sana Biotechnology SC451 (Priority 3 → 5)
- **Status:** IND filing still expected 2026, no new filing announcement as of April 12
- **Key data:** 14-month UP421 follow-up data published March 2026; hypoimmune islets survive and produce insulin without immunosuppression
- **Action:** Lowered priority to 5, monitor monthly

### 2. DAPAN-DIA Trial NCT06047262 (Priority 3 → 5)
- **Status:** Phase 2 still actively recruiting 300 T2D patients across Europe
- **Design:** Dapansutrile 1000mg BID vs placebo, 6 months, primary endpoint HbA1c
- **Action:** No interim results yet. Monitor quarterly.

### 3. AZD1656 ADOPTION Trial (Priority 4 → 5)
- **Status:** Ongoing, no published 2026 results
- **Details:** NCT05216172 testing AZD1656 100mg BID in 50 renal transplant + T2D patients
- **Mechanism:** Nature Cardiovasc Res paper confirms Treg mechanism in vivo
- **Action:** Monitor quarterly

### 4. SGLT2i + Colchicine Combination (Priority 4 → 5)
- **NEW FINDING:** PMID 40907678 — TriNetX retrospective analysis
  - 12,235 matched patients per arm (CAD + T2DM)
  - Combo SGLT2i + colchicine vs colchicine alone
  - Significant reductions in all-cause mortality, MACE, HF exacerbation
  - **Still retrospective only** — no prospective RCT registered
- **Action:** Added PMID as UNVETTED. Paper vetting queued for next run.

## Path Validation Fixes (from Run 22)
| Path | Status | Notes |
|------|--------|-------|
| verapamil → T1D | PARTIALLY_VALIDATED | Strong pediatric data, European RCT underpowered |
| dapagliflozin → inflammation | VALIDATED | Convergent NLRP3 mechanism, DAPAN-DIA recruiting |
| NLRP3 → inflammation | VALIDATED | Robust mechanistic evidence, RCT in progress |

**All 8/8 research paths now have validation status assigned.**

## Pipeline Status
All 39 improvement scripts: **[OK]**

## Credibility Sweep
- No PMIDs above 42000000 (fabricated): ✓
- No "zero SAEs" or "zero rejection" claims: ✓
- No overstated "achieves"/"curative" for preclinical: ✓

## State
- Papers: 244 total (244 vetted, 0 flagged, 0 unvetted) + 1 newly added unvetted
- Research Paths: 8 total (7 validated, 1 partially validated)
- Work Queue: 15 items remaining
- Git: Committed locally (push requires auth)
